Jan Jacob Schuringa
Overview
Explore the profile of Jan Jacob Schuringa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
2672
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huls G, Huls G, Woolthuis C, Schuringa J
Blood
. 2024 Dec;
145(6):561-566.
PMID: 39719041
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the (oligo)clonal expansion of myeloid progenitor cells. Despite advances in treatment, AML remains challenging to cure, particularly in patients...
2.
Hogeling S, Le D, La Rose N, Kwon M, Wierenga A, Van den Heuvel F, et al.
Haematologica
. 2024 Dec;
PMID: 39704147
Acute myeloid leukemia (AML) remains challenging to treat, which in part relates to genetic heterogeneity of the disease, to the protective tumor microenvironment driving resistance to therapy, and also to...
3.
de Weerd S, Ruiter E, Calicchia E, Portale G, Schuringa J, Roos W, et al.
Small Methods
. 2024 Oct;
8(12):e2400498.
PMID: 39431332
Cell membrane nanoparticles have attracted increasing interest in nanomedicine because they allow to exploit the complexity of cell membrane interactions for drug delivery. Several methods are used to obtain plasma...
4.
van Bergen M, Kamphuis P, de Graaf A, Salzbrunn J, Koorenhof-Scheele T, van Zeventer I, et al.
Am J Hematol
. 2024 Oct;
99(12):2402-2405.
PMID: 39429216
No abstract available.
5.
Dembitz V, Lawson H, Burt R, Natani S, Philippe C, James S, et al.
Leukemia
. 2024 Aug;
38(11):2395-2409.
PMID: 39187579
Identification of specific and therapeutically actionable vulnerabilities, ideally present across multiple mutational backgrounds, is needed to improve acute myeloid leukemia (AML) patients' outcomes. We identify stearoyl-CoA desaturase (SCD), the key...
6.
Kleftogiannis D, Gavasso S, Tislevoll B, van der Meer N, Motzfeldt I, Hellesoy M, et al.
iScience
. 2024 Jul;
27(7):110261.
PMID: 39021803
Mass cytometry by time-of-flight (CyTOF) is an emerging technology allowing for in-depth characterization of cellular heterogeneity in cancer and other diseases. Unfortunately, high-dimensional analyses of CyTOF data remain quite demanding....
7.
Kwon M, Thuring J, Querolle O, Dai X, Verhulst T, Pande V, et al.
Blood
. 2024 Jun;
144(11):1206-1220.
PMID: 38905635
The interaction between menin and histone-lysine N-methyltransferase 2A (KMT2A) is a critical dependency for KMT2A- or nucleophosmin 1 (NPM1)-altered leukemias and an emerging opportunity for therapeutic development. JNJ-75276617 (bleximenib) is...
8.
Groenen A, Halmos B, van Zeventer I, Salzbrunn J, Mayer M, La Rose N, et al.
Atherosclerosis
. 2024 Jun;
395:117609.
PMID: 38878675
Background And Aims: Previous studies have shown that skin autofluorescence (SAF), measured with an advanced glycation end product (AGE) reader, estimates the accumulation of AGEs in tissues. SAF is predictive...
9.
Lima K, Nogueira F, Cipelli M, Carvalho M, Pereira-Martins D, Silva W, et al.
Eur J Pharmacol
. 2024 Jun;
977:176723.
PMID: 38851560
Acute lymphoblastic leukemia (ALL), a complex malignancy, displays varying expression profiles of PIP4K2-related genes in adult patients. While PIP4K2A expression is elevated in ALL bone marrow cells compared to healthy...
10.
Rojas C, Pereira-Martins D, Bellido More C, Sternadt D, Weinhauser I, Hilberink J, et al.
Br J Haematol
. 2024 Apr;
204(6):2287-2300.
PMID: 38651345
Despite advancements in utilizing genetic markers to enhance acute myeloid leukaemia (AML) outcome prediction, significant disease heterogeneity persists, hindering clinical management. To refine survival predictions, we assessed the transcriptome of...